Literature DB >> 1732723

Activation of the transcription factor kappa B in human KG-1 myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine.

M A Brach1, S M Kharbanda, F Herrmann, D W Kufe.   

Abstract

The present studies have examined the effects of 1-beta-D-arabinofuranosylcytosine (ara-C) on activation of the transcription factor kappa B (NF-kappa B). The results demonstrate that treatment of human KG-1 myeloid leukemia cells with ara-C is associated with induction of protein binding to the NF-kappa B consensus sequence. NF-kappa B binding was activated at 30 min and reached maximal levels of binding at 1-2 hr of ara-C treatment. The NF-kappa B consensus sequence was ligated to the heterologous thymidine kinase (TK) promoter and the human growth hormone (GH) reporter gene to determine whether ara-C-induced NF-kappa B activity includes an enhancer function. Ara-C treatment had little effect on transient expression of pTKGH in KG-1 cells but increased transcription of the p (NF-kappa B) TKGH vector by 8-fold. The results also demonstrate that ara-C transiently increases NF-kappa B mRNA levels. However, the finding that ara-C-induced binding of NF-kappa B to DNA occurs in the presence of cycloheximide indicates that this agent activates preexisting NF-kappa B protein. These results suggest that ara-C induces a cytoplasmic pathway that transduces signals to the nucleus by activation of NF-kappa B.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732723

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells.

Authors:  B Piret; J Piette
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

Review 2.  Shared pathways: death receptors and cytotoxic drugs in cancer therapy.

Authors:  I Peták; J A Houghton
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 3.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Authors:  Eric R Gamazon; Jatinder K Lamba; Stanley Pounds; Amy L Stark; Heather E Wheeler; Xueyuan Cao; Hae K Im; Amit K Mitra; Jeffrey E Rubnitz; Raul C Ribeiro; Susana Raimondi; Dario Campana; Kristine R Crews; Shan S Wong; Marleen Welsh; Imge Hulur; Lidija Gorsic; Christine M Hartford; Wei Zhang; Nancy J Cox; M Eileen Dolan
Journal:  Blood       Date:  2013-03-28       Impact factor: 22.113

5.  Biological effects of a relatively low concentration of 1-beta-D-arabinofuranosylcytosine in K562 cells: alterations of the cell cycle, erythroid-differentiation, and apoptosis.

Authors:  H Yamada; J Horiguchi-Yamada; M Nagai; S Takahara; T Sekikawa; T Kawano; K Itoh; S Fukumi; S Iwase
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

6.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors:  Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

7.  Chemotherapy-related fever or infection fever?

Authors:  Nilgun Eroglu; Erol Erduran; Gokce Pinar Reis; Aysenur Bahadır
Journal:  Support Care Cancer       Date:  2020-08-12       Impact factor: 3.603

Review 8.  Targeting acute myeloid leukemia stem cell signaling by natural products.

Authors:  Kodappully Sivaraman Siveen; Shahab Uddin; Ramzi M Mohammad
Journal:  Mol Cancer       Date:  2017-01-30       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.